Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer.

Détails

ID Serval
serval:BIB_2BE25CF66B12
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer.
Périodique
Clinical cancer research
Auteur(s)
Ychou M., Azria D., Menkarios C., Faurous P., Quenet F., Saint-Aubert B., Rouanet P., Pèlegrin M., Bascoul-Mollevi C., Guerreau D., Saccavini J.C., Mach J.P., Artus J.C., Pèlegrin A.
ISSN
1078-0432
Statut éditorial
Publié
Date de publication
2008
Peer-reviewed
Oui
Volume
14
Numéro
11
Pages
3487-3493
Langue
anglais
Notes
Publication types: Clinical Trial, Phase II ; Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
PURPOSE: To evaluate the feasibility of radioimmunotherapy (RIT) with radiolabeled anti-carcinoembryonic antigen antibodies after complete resection of liver metastases (LM) from colorectal cancer. Patients and Methods: Twenty-two patients planned for surgery of one to four LM received a preoperative diagnostic dose of a 131I-F(ab')2-labeled anti-carcinoembryonic antigen monoclonal antibody F6 (8-10 mCi/5 mg). 131I-F(ab')2 uptake was analyzed using direct radioactivity counting, and tumor-to-normal liver ratios were recorded. Ten patients with tumor-to-normal liver ratios of >5 and three others were treated with a therapeutic injection [180-200 mCi 131I/50 mg F(ab')2] 30 to 64 days after surgery. RESULTS: Median 131I-F(ab')2 immunoreactivity in patient serum remained at 91% of initial values for up to 96 hours after injection. The main and dose-limiting-toxicity was hematologic, with 92% and 85% grades 3 to 4 neutropenia and thrombocytopenia, respectively. Complete spontaneous recovery occurred in all patients. No human anti-mouse antibody response was observed after the diagnosis dose; however, 10 of the 13 treated patients developed human anti-mouse antibody approximately 3 months later. Two treated patients presented extrahepatic metastases at the time of RIT (one bone and one abdominal node) and two relapsed within 3 months of RIT (one in the lung and the other in the liver). Two patients are still alive, and one of these is disease-free at 93 months after resection. At a median follow-up of 127 months, the median disease-free survival is 12 months and the median overall survival is 50 months. CONCLUSION: RIT is feasible in an adjuvant setting after complete resection of LM from colorectal cancer and should be considered for future trials, possibly in combination with chemotherapy, because of the generally poor prognosis of these patients.
Mots-clé
Adenocarcinoma/mortality, Adenocarcinoma/radiotherapy, Adult, Antibodies, Monoclonal/therapeutic use, Carcinoembryonic Antigen/immunology, Chemotherapy, Adjuvant, Colorectal Neoplasms/mortality, Colorectal Neoplasms/pathology, Female, Hepatectomy, Humans, Immunoglobulin Fab Fragments/therapeutic use, Iodine Radioisotopes/pharmacokinetics, Iodine Radioisotopes/therapeutic use, Liver Neoplasms/mortality, Liver Neoplasms/radiotherapy, Male, Middle Aged, Radioimmunotherapy/methods, Radiotherapy, Adjuvant
Pubmed
Web of science
Open Access
Oui
Création de la notice
18/11/2009 10:31
Dernière modification de la notice
08/05/2019 16:22
Données d'usage